Obsessive Compulsive Disorder (OCD)is a common and debilitating illness. For an unacceptable
proportion of patients, depressive symptoms remain impairing despite multiple treatments.
In August 2018, the FDA approved transcranial magnetic stimulation (TMS) for the treatment of
OCD based on a large study demonstrating efficacy. Our neurophysiological data and clinical
data in depression suggests that we can enhance the effects of TMS by using an adjunctive
medication called D-Cyloserine (DCS, 100mg) in conjunction with stimulation. The mechanism by
which this is achieved is called synaptic plasticity, or the activity dependent changes that
occur with brain stimulation.
Research Question and Objectives: To conduct a randomized sham- and placebo-controlled trial
of DCS in adjunct with rTMS in OCD. Participants will be randomized to receive 100mg of DCS
or placebo together with TMS.